Cronos Group (CRON) 주식 개요
는 캐나다, 이스라엘 및 전 세계에서 대마초 제품의 재배, 생산, 유통 및 마케팅에 종사하는 대마비노이드 회사입니다. 자세히 보기
CRON Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cronos Group Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | CA$4.67 |
| 52주 최고가 | CA$4.99 |
| 52주 최저가 | CA$3.23 |
| 베타 | 1.28 |
| 1개월 변동 | 1.97% |
| 3개월 변동 | 22.57% |
| 1년 변동 | 30.81% |
| 3년 변동 | 59.93% |
| 5년 변동 | -37.23% |
| IPO 이후 변동 | 462.65% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Aug 09
CRON: Buybacks And Higher Multiple Will Support A Stronger Outlook
Analysts have increased their Cronos Group price target by CA$1 to CA$6, reflecting updated assumptions regarding fair value, discount rate, growth, and margins following recent research updates. What’s in the News for Cronos Group Cronos Group announced a share repurchase program that allows the company to buy back up to 18,712,918 shares for $50 million.내러티브 업데이트 • Jun 28
CRON: Partial Rescheduling And Buybacks Will Support A Stronger Outlook
Analysts have raised their Cronos Group price target by CA$0.50 to CA$5.50, citing revised assumptions around higher projected revenue growth, a different discount rate, and updated margin and P/E expectations following recent research commentary and a more favorable view on partial cannabis re scheduling. Analyst Commentary Recent research on Cronos Group highlights how shifting views on cannabis policy and updated valuation work are feeding into more constructive analyst sentiment on the stock.
내러티브 업데이트 • Jun 14
CRON: Brand Strength And Rescheduling Tailwinds Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, with an updated fair value of CA$4.68 compared with the prior CA$4.24. This reflects refreshed views on revenue growth, margins, discount rates and future P/E assumptions following recent Street research, including the CA$1 target increase at TD Securities and supportive commentary around partial cannabis rescheduling from Roth Capital.
내러티브 업데이트 • May 31
CRON: Partial Rescheduling Expectations Will Constrain Future Earnings Power
Analysts have raised Cronos Group's CA$ price target by CA$1, citing updated expectations around revenue growth, margins and future P/E assumptions, as well as recent Street research that includes a CA$1 target increase at TD Securities and favorable perspectives on partial cannabis re-scheduling. Analyst Commentary Recent Street commentary around Cronos Group has focused on how updated revenue expectations, margin trajectories and P/E assumptions feed into revised valuation frameworks.내러티브 업데이트 • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.내러티브 업데이트 • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.내러티브 업데이트 • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.내러티브 업데이트 • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.내러티브 업데이트 • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.내러티브 업데이트 • Feb 27
CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.내러티브 업데이트 • Feb 13
CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.내러티브 업데이트 • Jan 30
CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.내러티브 업데이트 • Jan 16
CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).분석 기사 • Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...내러티브 업데이트 • Sep 04
GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).분석 기사 • Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
새로운 내러티브 • Apr 30
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.분석 기사 • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...분석 기사 • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...분석 기사 • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...주주 수익률
| CRON | CA Pharmaceuticals | CA 시장 | |
|---|---|---|---|
| 7D | 3.3% | -2.8% | 0.2% |
| 1Y | 30.8% | 7.1% | 20.9% |
수익률 대 산업: CRON은 지난 1년 동안 7.1%의 수익을 기록한 Canadian Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: CRON은 지난 1년 동안 20.9%를 기록한 Canadian 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 8.2% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 16.0% |
| 10% least volatile stocks in CA Market | 3.6% |
안정적인 주가: CRON는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: CRON의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
는 캐나다, 이스라엘 및 전 세계에서 대마초 제품의 재배, 생산, 유통 및 마케팅에 종사하는 대마초 회사입니다. 이 회사는 말린 꽃, 프리롤, 오일, 기화기, 식용 및 대마초 팅크를 Spinach, Lord Jones 및 PEACE NATURALS 브랜드 이름으로 제공합니다. 이 회사는 캐나다 스테이너에 본사를 두고 있습니다.
Cronos Group Inc. 기초 지표 요약
| CRON 기초 통계 | |
|---|---|
| 시가총액 | CA$1.72b |
| 순이익 (TTM) | CA$97.91m |
| 매출 (TTM) | CA$250.57m |
17.6x
주가수익비율(P/E)6.9x
주가매출비율(P/S)CRON는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| CRON 손익계산서 (TTM) | |
|---|---|
| 매출 | US$179.09m |
| 매출원가 | US$102.05m |
| 총이익 | US$77.04m |
| 기타 비용 | US$7.06m |
| 순이익 | US$69.98m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 0.19 |
| 총이익률 | 43.02% |
| 순이익률 | 39.08% |
| 부채/자본 비율 | 0% |
CRON의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/21 06:47 |
| 종가 | 2026/09/18 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Cronos Group Inc.는 16명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |